Valion Bio, Inc.

Valion Bio, Inc. (TIVC) priced its initial public offering on Nov 12, 2021 at $5.00 per share, raising $15M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $46.3M. ThinkEquity was lead-left underwriter. Procopio, Cory, Hargreaves & Savitch and Carter Ledyard & Milburn advised the company and Gracin & Marlow advised the underwriters.

At its 2021 IPO, Tivic Health Systems, Inc. (now Valion Bio, Inc.) was a commercial-phase bioelectronic medicine company. Its first product, ClearUP Sinus Relief, is a handheld FDA- and CE-cleared device using low-current electrical waves to relieve sinus and nasal inflammation.

Status

IPO

Ticker

TIVC

Exchange

Nasdaq Capital Market

Priced

Nov 12, 2021

IPO price

$5.00

Raised

$15M

Market cap at IPO price

$46.3M

First filed

Aug 3, 2021

Underwriters

ThinkEquity

Company counsel

Procopio, Cory, Hargreaves & Savitch and Carter Ledyard & Milburn

Underwriters' counsel

Gracin & Marlow

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.